FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

The FDA has approved ZORYVE cream 0.3% for treating plaque psoriasis in children as young as age 2, marking the first once-daily, non-steroidal therapy for this indication. This is Arcutis' seventh FDA approval for ZORYVE in four years. The approval addresses a significant treatment gap for young children with plaque psoriasis, offering a steroid-free option suitable for use anywhere on the body with no duration restrictions.

06/29/2026, 7:06 PM • GlobeNewswire

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares worth $121,000 on June 15, 2026, under a pre-arranged trading plan. The sale reduced her stake by 15% but she retains over 27,500 shares. The insider transaction appears routine amid strong company performance, with ZORYVE revenue climbing 65% year-over-year to $105.4 million in Q1, and the company narrowing quarterly losses while maintaining positive cash flow.

06/23/2026, 7:15 PM • The Motley Fool

Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors. Leonard brings 30 years of biopharmaceutical industry experience, including previous roles as Chairman and CEO of Unity Biotechnology and co-founder/CEO of Kythera Biopharmaceuticals. The appointment comes as Antag prepares to initiate Phase 2a trials of AT7687, its lead GIPR antagonist candidate for obesity treatment.

06/09/2026, 7:00 AM • GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics granted an aggregate of 44,000 restricted stock units to six newly hired employees as a material inducement for employment. The RSUs vest over four years with 25% vesting annually, subject to continuous employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan.

06/05/2026, 4:00 PM • GlobeNewswire

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Arcutis Biotherapeutics announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami. The commercial-stage biopharmaceutical company, focused on immuno-dermatology innovations, will participate in a fireside chat. The company also reported first quarter 2026 financial results and provided a business update.

05/26/2026, 4:00 PM • GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics granted 269,000 restricted stock units and options for 70,000 shares to 40 newly hired employees as inducement awards. The company also submitted a supplemental New Drug Application to the FDA to expand ZORYVE cream's indication to treat atopic dermatitis in infants as young as 3 months, supported by Phase 2 study data.

05/08/2026, 4:00 PM • GlobeNewswire

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4 million for ZORYVE (roflumilast), representing 65% year-over-year growth despite 17% sequential decline due to typical Q1 seasonality. The company submitted a supplemental New Drug Application to expand ZORYVE cream 0.05% for treating atopic dermatitis in infants ages 3-24 months, completed enrollment in a foam formulation trial for pediatric psoriasis, and initiated a Phase 1 study for investigational ARQ-234. The company maintained positive operating cash flow of $2.2 million and reaffirmed full-year 2026 revenue guidance of $480-495 million.

05/06/2026, 4:00 PM • GlobeNewswire

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Arcutis Biotherapeutics announced it will report first quarter 2026 financial results on May 6, 2026, followed by a conference call at 4:30pm ET. The company also presented new Phase 2 results in infants with atopic dermatitis at the 2026 American Academy of Dermatology Annual Meeting and will present at the 25th Annual Needham Virtual Healthcare Conference.

04/15/2026, 4:00 PM • GlobeNewswire

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know

Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares worth $239,000 on April 1, 2026, under a pre-planned 10b5-1 trading plan adopted in March 2025. The sale represents a routine liquidity event rather than a loss of confidence, as the company's stock has surged 65% over the past year. Arcutis is transitioning from development to commercialization, with its ZORYVE eczema cream generating $372.1 million in net product revenue in 2025 (up 123% year-over-year) and achieving positive operating cash flow.

04/08/2026, 7:30 AM • The Motley Fool

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

Arcutis Biotherapeutics announced its Q4 and full year 2025 financial results and provided a business update. The company will present at the TD Cowen 46th Annual Health Care Conference on March 2-4, 2026, in Boston. Arcutis also announced that professional golfer Max Homa has joined its 'Free to Be Me' campaign to raise awareness about seborrheic dermatitis treatments.

02/27/2026, 4:00 PM • GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Arcutis Biotherapeutics reported Q4 2025 net product revenue of $127.5 million for ZORYVE (roflumilast), an 84% increase year-over-year, with full-year 2025 revenue reaching $372.1 million (123% growth). The company achieved positive operating cash flow, raised 2026 guidance to $480-495 million, and reported positive Phase 2 trial data for pediatric atopic dermatitis. The company is expanding its dermatology sales force and assuming direct responsibility for pediatric and primary care commercialization.

02/25/2026, 4:00 PM • GlobeNewswire

This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Tejara Capital exited its entire position in Arcutis Biotherapeutics, selling 520,503 shares for approximately $9.81 million in February 2026. The stock has surged 99.1% over the past year, driven by strong Q3 results showing net product revenue more than doubling year-over-year. The fund's exit appears to be risk management after the sharp Q4 rally rather than a bearish signal, as the company maintains confidence in its commercial trajectory with 2026 guidance of $455-470 million in net product sales.

02/06/2026, 5:18 AM • The Motley Fool

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics granted 94,000 restricted stock units to 12 newly hired employees as an inducement for employment. The awards were approved by the Compensation Committee under the 2022 Inducement Plan with a grant date of February 2, 2026, and vest over four years with 25% vesting annually.

02/05/2026, 4:00 PM • GlobeNewswire

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Arcutis Biotherapeutics announced it will report Q4 and full year 2025 financial results on February 25, 2026, followed by a conference call at 4:30 p.m. ET. The company will also present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. Arcutis highlighted 2026 strategic priorities and announced a nationwide survey addressing concerns about topical steroid use and the need for long-term treatment strategies for chronic inflammatory skin conditions.

01/22/2026, 4:00 PM • GlobeNewswire

Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions

A nationwide survey of 1,500 respondents reveals that nearly 9 in 10 adults and parents with chronic inflammatory skin conditions are concerned about topical steroid side effects, and approximately 8 in 10 report their treatment plans focus on reactive flare management rather than proactive long-term disease management. The survey highlights significant emotional and social burdens when skin conditions are uncontrolled, with many patients avoiding social activities and experiencing anxiety.

01/21/2026, 8:00 AM • GlobeNewswire